cut_t_wires_banner.gif
Google Search
23496094 Visitors
 HOME
 Obituaries 5-28
 Yahoo Comic Strips
 Daily Crossword
 Today's Trivia
 Daily Horoscopes
GAMES
 ARCADE
 Sheepish
 Shootem In
 Master Solitaire
 Trap Shooter
 Crypt Raider
 Pharaoh's Tomb
 HANGAROO
Area Towns
 EMERGENCY #s
 Berryville
 Eureka Springs
 Green Forest
 Holiday Island
Local Schools
 Berryville
 Clear Spring
 Eureka Springs
 Green Forest
Nat/Int News
 Top Stories
 World
 Business
 Sports
 Entertainment
 Health
 Politics
 Technology
 Science
 Opin/Editorial
 Oddly Enough

Newsfeeds

Business
Thu, 28 May 2020 13:50
Yahoo News - Latest News &Headlines
COP26 climate talks set to be pushed back a yearCritical UN climate talks at which nations were expected to ramp up plans to combat global warming are to be pushed back a full year to November 2021, observers to the negotiations have told AFP. Current national pledges submitted in annex to the 2015 Paris Agreement would allow the planet's surface to warm three degrees Celsius above pre-industrial levels, far above the ceiling of "well below" 2C -- and 1.5C if feasible -- agreed to in the landmark treaty.
COP26 climate talks set to be pushed back a year
N.J. Sees $10 Billion Gap Growing With One in Nine Jobless(Bloomberg) -- New Jersey, confronting a projected $10.1 billion revenue shortfall through fiscal 2021, expects an even bigger hole if the new coronavirus resurges toward year’s end, as some health experts expect.State Treasurer Elizabeth Muoio, in live video testimony before the state Assembly budget committee, said the shortage could grow another $1 billion should the state reverse its progress on slowing the virus’ spread.Her update came as Governor Phil Murphy said more than one in nine New Jersey residents, or 1.17 million people, are now without a job. He said 911,000 people in the state were on unemployment.Muoio said the state has spent about $500 million fighting Covid-19, which has taken the lives of 11,401 in the state. The number of new cases rose by 1,261 to 157,815, an increase of 0.8% that outpaced the prior seven-day average of 0.6%.Next week, the full Assembly is scheduled to vote on Murphy’s pitch to issue billions of dollars in short- and long-term debt, including the U.S. Federal Reserve’s Municipal Liquidity Facility, to patch thebudget holes.“Without more robust and flexible federal aid -- as well as the ability to borrow -- additional, substantial cuts will be necessary to produce a balanced FY 2021 budget,” Muoio said. If the $2.4 billion received so far isn’t spent according to U.S. Treasury guidelines, she said, “it may result in the claw-back of these funds.”Muoio forecast a fiscal 2020 ending balance of more than $1 billion less than originally expected. By June 30, the typical last day of the spending year, the state expects to have $344 million on hand, she said. On Sept. 30 -- the last day of a fiscal year extended in an emergency step by the governor -- the total should be $494 million.Not Advisable“That type of surplus balance might have been customary during the last administration, but it’s anything but advisable,” said Muoio, a reference to thin year-end cushions during Republican Governor Chris Christie’s two terms, when revenue routinely failed to hit targets.Muoio last week announced $5 billion in cuts and delayed spending through June 2021. If more federal cash isn’t forthcoming, Murphy has warned, the public workforce will be slashed.A $951 million pension payment, due in September, will be paid the next month, according to a revised spending plan. Other September-to-October deferrals include $467 million for school aid; $354 million for municipal property-tax relief; $250 million for special education; and $28 million in budget aid to distressed cities.Muoio said the state is going to require federal assistance and the ability to access borrowing facilities in order to meet its obligations. “We are eager to disburse these funds where they are needed most,” she said.At his daily news briefing, the governor said the state’s testing capacity is “almost exploding.” One day last week, the state reported in excess of 30,000 tests conducted -- a sign, Murphy said, that New Jersey can reach his goal of 20,000 daily tests by month’s end. Broad testing and contact tracing must be in place, he says, before the state can fully reopen.Over the past 24 hours, 287 hospitalized patients were discharged. But Murphy said 365 new admissions were data his administration was “very much looking at,” because it was an unusual spike. It was too early to say whether that figure represented a reversal of the virus’ slowdown in New Jersey, he said, but he reiterated the need to continue social distancing.(Updates with revenue forecast throughout.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
N.J. Sees $10 Billion Gap Growing With One in Nine Jobless
The Vehicle Leasing Market is expected to grow by $ 56.58 bn during 2020-2024 progressing at a CAGR of 3% during the forecast periodVehicle Leasing Market In Europe 2020-2024 The analyst has been monitoring the vehicle leasing market in Europe and it is poised to grow by $ 56.58 bn during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on vehicle leasing market in Europe provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. Read the full report: https://www.reportlinker.com/p05136844/?utm_source=PRN The report offers an up-to-date analysis regarding the current Europe market scenario, latest trends and drivers, and the overall market environment. The market is driven cost-effective way of obtaining a vehicle, growing demand for vehicle leasing from SMEs, and rising technological obsolescence of older vehicles. In addition, Cost-effective way of obtaining a vehicle is anticipated to boost the growth of the market as well. The vehicle leasing market in Europe market analysis include type segment and geographic landscapes The vehicle leasing market in Europe is segmented as below: By Type • Passenger cars • Commercial vehicles By Geographic Landscapes • UK • Germany • France • Rest of Europe This study identifies use of telematics in leased vehicles as one of the prime reasons driving the vehicle leasing market in Europe growth during the next few years. Also, car subscription model of car leasing, and rising demand for EV leasing due to the need for optimum performance and reduction of emissions will lead to sizable demand in the market. "The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our vehicle leasing market in Europe covers the following areas: • Vehicle leasing market in Europe sizing • Vehicle leasing market in Europe forecast • Vehicle leasing market in Europe industry analysis" Read the full report: https://www.reportlinker.com/p05136844/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
The Vehicle Leasing Market is expected to grow by $ 56.58 bn during 2020-2024 progressing at a CAGR of 3% during the forecast period
Swell Fitness Reviews the Resurge HGH Support SupplementOne of the latest reviews available on the deep support and HGH support supplement Resurge comes from Swell Fitness.
Swell Fitness Reviews the Resurge HGH Support Supplement
Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine®  in Respiratory Illness in Patients with COVID-19 at Singapore General HospitalPartner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine (sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital (NCT04400929). The study will evaluate the effect of Leukine on lung function and other important patient outcomes.
Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital
Blue Shield of California Provides Additional $300,000 in Grants to Community Groups Supporting Youth Mental HealthBlue Shield of California continues to show its commitment to youth resilience programs in California, announcing another $300,000 in grants to nonprofit organizations providing mental health supports in San Diego and Alameda counties. This builds on the company's multi-year, $10 million investment in youth mental health.
Blue Shield of California Provides Additional $300,000 in Grants to Community Groups Supporting Youth Mental Health
Wild Florida hosts 4th Annual Gator Week promoting alligator conservation &family funIt's no secret Wild Florida knows a thing or two about alligators. To share this knowledge and passion with visitors, Wild Florida will host its 4th Annual Gator Week June 8-13, and offer free admission to its Gator Park for the heroes of the Covid-19 crisis including first responders and essential workers.
Wild Florida hosts 4th Annual Gator Week promoting alligator conservation &family fun
French way of life to resume with restaurants reopeningIn a speech on Thursday, Prime Minister Edouard Philippe promised that “freedom will, at last, again become the rule.” There's a notable exception for the Paris region, the country's worst-affected by the virus, where many facilities will have to wait until June 22 to reopen. Philippe said the French are yearning for cafes and restaurants to reopen, noting that these “are part of our art of living.”
French way of life to resume with restaurants reopening
Artist Shantell Martin and Baronfig Create Journal For Staying Present While At HomeSimple Observations is a prompted journal that encourages users to set aside time to observe and be present. The journal features Shantell Martin's signature black and white hand-drawn style, and inspiring question-based prompts.
Artist Shantell Martin and Baronfig Create Journal For Staying Present While At Home
House Votes to Extend Popular Small Business Loan Program(Bloomberg) -- The House voted Thursday to give small businesses financially strapped by the Covid-19 crisis more flexibility to spend forgivable loans for payrolls and expenses from the government’s popular Paycheck Protection Program.The 417-1 vote sends the measure to the Senate, which may seek changes. The bill’s sponsors say urgent action is needed because the eight-week period when proceeds must be spent for loans to be forgiven will begin expiring Friday for the first loan recipients after the Small Business Administration program opened April 3.The House measure would give companies much more time to spend the money -- within 24 weeks or until the end of the year, whichever comes first -- and still qualify to have their PPP loans forgiven. Businesses would also have up to five years, instead of two years, to repay any money owed on a loan and could use a greater percentage of proceeds on rent and other approved non-payroll expenses.“The true emergency period has evolved over time and this bill addresses that,” said Steve Chabot of Ohio, the top Republican on the Small Business Committee. “The flexibility that this allows America’s small businesses is going to go a long way to address the concerns we have heard time and time again.”Bill co-sponsor Dean Phillips, a Minnesota Democrat, said restaurants and hospitality businesses are especially in need of the new flexibility because many employees haven’t been able allowed to return to work.“This bill will help people in ways they need, and we have not a moment to lose,” Phillips said, urging colleagues to “listen to our 11 million restaurant employees.”The measure’s Republican co-sponsor,Chip Roy of Texas, said businesses are having difficulty meeting the deadline to rehire workers in part because expanded unemployment insurance is discouraging employees from coming back to work.The Senate is expected to take up the bill next week. House Majority Leader Steny Hoyer said Tuesday theHouse and Senate should be able to quickly agree on changes.But Senate Small Business Chairman Marco Rubio, a Florida Republican, said in a statement that some provisions in the House bill “could create an unintended disincentive to rehiring and create new and serious burdens for PPP borrowers interms of forgiveness.” He said he will work to ensure that “necessary changes to increase flexibility do not inadvertently harm business owners and employees in the process.”Changed ProvisionsThe House bill, H.R. 7010, would lower to 60% the current requirement that 75% of a loan be used on payroll. Restaurants and other small businesses have said they want flexibility to spend more on overhead expenses, especially in high-rent areas.The measure would change documentation requirements for employers who say they’ve been unable to rehire laid-off employees. Under the program, the amountof loan forgiveness is reduced if companies don’t maintain head count and salaries. The bill also clarifies that a borrower doesn’t have to start repaying a loan until the SBA determines whether it can be forgiven.Also, employers would be required to comply with coronavirus safety standards.Rubio contends the House language creates a problem for companies that use less than 60% of a loan on payroll. The current PPP program allows partial loan forgiveness if a company uses less than 75% of a loan for payroll, but the House bill appears to state that none of the loan would be forgiven if the 60% threshold isn’t met.Rubio also says the new certification on inability to rehire employees is too broad and would give businesses less incentive to rehire.Differences over these matters could lead the Senate to amend the bill and send it back for further House action.Funding LevelThe PPP, the centerpiece of the $2.2 trillion relief package Congress enacted in March, allows loans of as much as $10 million that can be forgiven if a business spends it within eight weeks on payroll and no more than 25% for rent and other approved expenses.The idea was to help businesses keep workers on thepayroll while they were closed during stay-at-home orders, so they could be ready to reopen when the bans lifted. But restaurants and other small businesses have said they need more time to spend the funds because they won’t be ready to reopen or be fully functional at the end of eight weeks.The second round of $320 billion in PPP funding began April 27 after an initial allocation of $349 billion was exhausted in just 13 days. The SBA reported on its website that more than 4.4 million loans worth $510.5 billion had been approved as of Wednesday night, meaning about $130 billion remains.(Updates with Rubio comment in ninth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
House Votes to Extend Popular Small Business Loan Program
Nissan To Close Plants In Spain And IndonesiaNissan Motor Company says it will be closing auto plants in Spain and Indonesia as part of a four-year plan to correct its financial situation. News of the plants closings prompted protests in Spain over the loss of jobs amid economic recovery efforts during the COVID-19 pandemic. The Associated Press reports that the losses mark Nissan’s first annual loss since 2009.
Nissan To Close Plants In Spain And Indonesia
A Trio of Potentially Underestimated Stocks to Consider2 key valuation ratios may signal potential bargains Continue reading...
A Trio of Potentially Underestimated Stocks to Consider
global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030Global Viral Vector and Plasmid Manufacturing Market to Reach $5.86 Billion by 2030Read the full report: https://www.reportlinker.com/p05902571/?utm_source=PRN Market Report Coverage - Viral Vector and Plasmid ManufacturingMarket Segmentation• Vector Type – Plasmid DNA and Viral Vector• Viral Vector Type – Adenovirus, Adeno-Associated Virus, Retrovirus, Lentivirus, Vaccinia Virus, and Other Viral Vectors• Disease Type – Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, and Other Diseases• Application –Gene Therapy, Cell Therapy, Vaccinology, and Other ApplicationsRegional Segmentation• North America – U.S., Canada• Europe – Germany, U.K., France, Italy, Switzerland, Belgium, Spain, and Rest-of-Europe• Asia-Pacific – China, Australia, Japan, India, South Korea, Singapore, and Rest-of-Asia-Pacific• Rest-of-the-World – Latin America and Middle-East and AfricaGrowth Drivers• Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases• Rapid Uptake of Viral and Plasmid Vectors for the Development of Innovative Therapies• Increasing Number of Clinical Studies for the Development of Gene Therapy• Favorable Funding Scenario for Vector-Based TherapiesMarket Challenges• Unaffordable Cost of Gene Therapies• High Manufacturing Costs of Viral Vectors and Plasmids• Complications Associated with Large-Scale Production of VectorsMarket Opportunities• Rising Demand for Synthetic Genes• Emergence of Next-Generation VectorsKey Companies ProfiledFUJIFILM Holdings Corporation, GENERAL ELECTRIC, Lonza, Merck KGaA, MolMed S.p.A., Novasep Holding, Oxford Biomedica plc, Catalent, Inc., Thermo Fisher Scientific, Inc., GenScript, Boehringer Ingelheim, Wuxi AppTec Co., Ltd., Sartorius AG, Takara Bio Inc., and Aldevron, L.L.C.Key Questions Answered:• What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?• What are the major advancements in the viral vector and plasmid manufacturing sector? What are the key trends of the global viral vector and plasmid manufacturing market? How is the market evolving and what is its future scope? • What are the major drivers, challenges, and opportunities of the global viral vector and plasmid manufacturing market?• What are the key developmental strategies implemented by the key players of the global viral vector and plasmid manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?•What is the regulatory scenario of the global viral vector and plasmid manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral vector and plasmid manufacturing products?• What are major milestones in patenting activity in the global viral vector and plasmid manufacturing market? • What was the market size of the global viral vector and plasmid manufacturing market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global viral vector and plasmid manufacturing market during the period between 2020 and 2030?• What is the global market size for manufacturing plasmids and different types of viral vectors available in the global viral vector and plasmid manufacturing market in 2019? What are the key trends of the market with respect to different vectors and which vector type is expected to dominate the market during the forecast period 2020-2030?• What are the different disease areas where plasmids and viral vectors are employed in the global viral vector and plasmid manufacturing market? Which disease type dominated the market in 2019 and is expected to dominate in 2030?• What are the different applications associated with viral vector and plasmid manufacturing? What was the contribution of each of the application areas in the global viral vector and plasmid manufacturing market in 2019, and what is it expected in 2030?• Which region is expected to contribute the highest sales to the global viral vector and plasmid manufacturing market during the period between 2019 and 2030? Which region and country carry the potential for significant expansion of key companies in the viral vector and plasmid manufacturing market? What are the leading countries of different regions that contribute significantly toward the growth of the market?• Which are the key players of the global viral vector and plasmid manufacturing market, and what are their roles in the market? What was the market share of the key playersin 2019?Market OverviewThe ability of vectors to carry out genetic modification through the introduction of therapeutic DNA/gene into a patient's body or cell has enabled its application in a wide range of modern therapies, including cell and gene therapies.Growing prominence of these therapies in different medical applications has therefore resulted in an increased demand for both viral and non-viral vectors.Vector-based therapies are currently being used for the treatment of a large number of diseases, including cancer, infectious diseases, genetic diseases, and cardiovascular diseases, among others.Viral vectors and plasmid reduce the cost of treatment and help in decreasing repeated administrations of medications.Moreover, vectors are also increasingly being used in the field of vaccinology for the development of vaccines owing to the advantage offered by them in inducing a wide range of immune response types. Several players, including biopharmaceutical companies, research institutes, contract manufacturing organizations, and non-profit organizations, have therefore focussed their interest on the development and production of viral vectors and plasmids.Our healthcare experts have found viral vector and plasmid manufacturing industry to be one of the most rapidly evolving markets, and the global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030. The market is driven by certain factors, which include success of vector-based cell and gene therapies in treating various therapeutic conditions, increasing number of clinical studies in the field of gene therapy and availability of funding for vector-based gene therapy development, technological advancements in the biomanufacturing sector, and growing investments for expanding vector manufacturing facilities. The market is favoured by the rising prevalence of genetic disorders, cancer, and infectious diseases that has raised the demand for advanced therapeutics and increasing acceptance for comparatively newer treatment options in developing countries.However, the growth of the market is also affected by several factors.Exorbitant manufacturing cost and highly regulated processes for large-scale vector production are the key challenges cited by industry experts.In addition, lack of required infrastructure and the shortfall of expertise in terms of scale, complexities, and quality assurance for vector production are some of the factors restraining the market growth.However, rise of contract manufacturers has effectively addressed the above-articulated manufacturing challenges by offering a wide range of vector manufacturing services that offer lucrative opportunities for the growth of the market. Further, increase in research and developmental activities in vector engineering offers strong promise to drive the growth of the viral vector and plasmid manufacturing market in the upcoming years.Within the research report, the market is segmented on the basis of vector type, application, disease, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the application of viral vector and plasmid in various therapies on the global level has created a buzz among companies to invest significantly in viral vector and plasmid manufacturing market.The market is highly competitive, marking the presence of several contract manufacturing organizations and biopharmaceutical companies, who are engaged in in-house vector manufacturing.Among the different players of the market, Lonza and Thermo Fisher Scientific hold majority of the market share. Other companies contributing significantly toward the growth of the global viral vector and plasmid manufacturing market include GE Healthcare, Fujifilm Holding Corporation, Merck KGaA, Oxford Biomedica plc, Sartorius AG, and Catalent, Inc., among others. On the basis of region, North America holds the largest market share, while Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period.Countries Covered• North America• U.S.• Canada• Europe• U.K.• Germany• France• Spain• Italy• Switzerland• Belgium• Rest-of-Europe• Asia-Pacific• China• Japan• Australia• South Korea• India• Singapore• Rest-of-Asia-Pacific• Rest-of-the-WorldRead the full report: https://www.reportlinker.com/p05902571/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030
Google makes sharing Plus Codes easier in a push to simply addressing system globallyTwo years ago, Google unveiled Plus Codes, a digital addressing system to help billions of people navigate to places that don’t have clear addresses. The company said today it is making it easier for anyone with an Android device to share its rendition of an address -- a six-digit alphanumeric code. Google Maps users on Android can now tap the blue dot that represents their current location to generate and share their unique six-digit coordinate with friends.
Google makes sharing Plus Codes easier in a push to simply addressing system globally
The American Economy Runs on ACH, Says Mercator Advisory Group White PaperThe ACH Network is woven into the daily payment activity of American consumers, businesses and government, says a Mercator Advisory Group white paper published today titled, "The Expanding Role of ACH in the Era of Faster Payments." The paper also highlights how – as payments become faster – ACH supports the future of the industry with Same Day ACH, while providing the money-movement infrastructure for many other payment products.
The American Economy Runs on ACH, Says Mercator Advisory Group White Paper

 INSURANCE
Browser Prefs
Add to Favorites
Make Home Page
Arcade Hi Scores
Snake:
15000
By: I DID NOT CHEAT
Tetris:
2147483647
By: PLAYED BY MASTER
Asteroids:
2147483647
By: WORLD RECORD
Invaders:
2147483647
By: YOU DID HACK IT
Pacman:
200000
By: GAME OVER
ABC News
 World News
 U.S. News
 Politics
 MONEYScope
 SciTech
 Entertainment
 Travel
 Health
 Relationships
 GMA
 Nightline
 Primetime
 20/20
 WNT

NWADN.com disclaims all liability or responsibility for any loss or damage that may result from the action or
failure to act or not act by any person in regards to any information provided within this website.